Levodopa/carbidopa subcutaneous - NeuroDerm

Drug Profile

Levodopa/carbidopa subcutaneous - NeuroDerm

Alternative Names: Carbidopa/levodopa subcutaneous - NeuroDerm; ND-0612; ND-0612H; ND-0612L; ND-0680

Latest Information Update: 10 Mar 2017

Price : $50

At a glance

  • Originator NeuroDerm
  • Class Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
  • Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Parkinson's disease

Most Recent Events

  • 02 Mar 2017 NeuroDerm terminates its planned pharmacokinetic clinical trial (Trial 009) for Parkinson's disease based on its modified EU clinical and regulatory development strategy
  • 01 Mar 2017 NeuroDerm plans to obtain a broader label for levodopa/carbidopa for Parkinson's disease in the EU based on the BeyoND and the amended iNDiGO trial
  • 01 Mar 2017 Interim efficacy and safety data from a phase II trial in Parkinson's Disease released by NeuroDerm
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top